Logo from Curevac
Photo: THOMAS KIENZLE / AFP
The Tübingen-based biotech company Curevac will also have its corona vaccine manufactured by Novartis.
The Swiss group will start producing the vaccine candidate CVnCoV, said Curevac.
Preparations for the start of production, the technology transfer and the test runs have therefore already begun.
Novartis aims to produce up to 50 million cans by the end of 2021 and up to around 200 million cans in 2022.
Deliveries from the production site in Kundl in Austria are expected to start in summer 2021.
"Together with our new partner, we can significantly increase our production capacities and place our production network on an even broader basis," said Curevac board member Florian von der Mülbe.
In autumn 2020, Curevac started building a European network for vaccine production with several partners from the pharmaceutical industry.
So far, Curevac has signed agreements with Bayer, Fareva, Wacker, Rentschler and others.
The Bayer Group in Leverkusen alone wants to produce 161 million doses of the Curevac vaccine this year.
The European Medicines Agency (EMA) started the rapid testing procedure for the Curevac vaccine in mid-February.
The decision is based on the preliminary results of laboratory tests and clinical studies.
According to the EMA, this makes it clear that the vaccine stimulates the production of antibodies against the coronavirus.
Icon: The mirror
fdi / ssu / dpa